search
Back to results

Stereotaxis Study To Obliterate Persistent Ventricular Tachycardia (STOP-VT)

Primary Purpose

Ventricular Tachycardia

Status
Completed
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
Magnetic irrigated ablation catheter
Sponsored by
Stereotaxis
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Ventricular Tachycardia focused on measuring arrhythmia, ventricular tachycardia, ablation, mapping, electrophysiology

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subject must be between the ages of 18 - 80 years
  • Willing to provide prior written informed consent per local ethics committee guidelines
  • Subjects must present with ventricular tachycardia, characterized by: history of myocardial scar and spontaneous ventricular tachycardia
  • Able to be safely exposed to static magnetic fields
  • No in-situ devices are present or any in-situ devices have been verified to be compatible to magnetic fields

Exclusion Criteria:

  • Presence of a mobile ventricular thrombus
  • Inability to access the left ventricle
  • Subjects must not have any contraindications to short-term anticoagulation
  • Subjects must not have a life expectancy of <1 year due to a medical illness

Sites / Locations

  • Krannert Institute of Cardiology
  • Hospital of the University of Pennsylvania
  • Na Homolce Hospital
  • Herzzentrum Universitat Leipzig

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Magnetic irrigated ablation catheter

Arm Description

Patients with documented VT and prior MI, in whom an ICD was implanted either for primary or secondary prevention, were recruited for endocardial mapping/ablation during VT (entrainment mapping, activation mapping) and/or substrate mapping in sinus rhythm (elimination of fractionated/late potentials, endocardial scar homogenization) with remote magnetic navigation (Niobe, Stereotaxis Inc.,St Louis, USA) and irrigated RF ablation (NaviStar RMT ThermoCool, Biosense Webster,California, USA).

Outcomes

Primary Outcome Measures

Percentage of Participants Free From VT at 1 Year Post-Treatment
In order to qualify for inclusion in the chronic success statistic, patients must first be an acute success and must have had no VTs identified in their ICD history post ablation therapy.

Secondary Outcome Measures

Full Information

First Posted
February 24, 2009
Last Updated
July 27, 2015
Sponsor
Stereotaxis
search

1. Study Identification

Unique Protocol Identification Number
NCT00851279
Brief Title
Stereotaxis Study To Obliterate Persistent Ventricular Tachycardia
Acronym
STOP-VT
Official Title
Stereotaxis Study To Obliterate Persistent Ventricular Tachycardia: Data Collection of Clinical Scar-related VT Cases
Study Type
Interventional

2. Study Status

Record Verification Date
July 2015
Overall Recruitment Status
Completed
Study Start Date
June 2009 (undefined)
Primary Completion Date
October 2012 (Actual)
Study Completion Date
April 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Stereotaxis

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a prospective, non-randomized, multi-center clinical case series evaluating the outcomes of the magnetic navigation system in ventricular tachycardia (VT) cases. Subjects will be evaluated acutely and will be followed clinically at 1, 6 and 12 months post-treatment.
Detailed Description
Catheter ablation of ventricular tachycardia (VT) is greatly facilitated by using a substrate mapping approach - that is, mapping of the left ventricle during sinus or paced rhythm to identify diseased myocardium. Using three dimensional electroanatomical mapping, it is possible to reconstruct an anatomical rendering of the left ventricle based on voltage. For hemodynamically stable or unstable VTs, various electrophysiologic maneuvers can then be used to identify the critical portions of the VT circuit within the scar (entrainment mapping, identification of diastolic potentials, identification of electrically-unexcitable scar, fractionated potentials and pace mapping). These methods are limited by the resolution of the substrate map, accuracy of catheter manipulation, and operator skill. To this end, a magnetic navigation system has been developed that allows for remote cardiac mapping. When used in concert with a compatible electroanatomical mapping system, it is possible to create a high-density ventricular substrate map of healed myocardial infarction. By removing the necessity for technical skill with catheter manipulation, this system has the potential for both improving the efficacy of VT ablation and expanding the clinical use of this substrate mapping approach. Recently, a higher-powered, irrigated tip catheter has become available in certain markets for use in cardiac arrhythmia ablations. This study will evaluate the outcomes of using this magnetic irrigation ablation catheter during mapping and ablation of VT while also using remote magnetic navigation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ventricular Tachycardia
Keywords
arrhythmia, ventricular tachycardia, ablation, mapping, electrophysiology

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
53 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Magnetic irrigated ablation catheter
Arm Type
Experimental
Arm Description
Patients with documented VT and prior MI, in whom an ICD was implanted either for primary or secondary prevention, were recruited for endocardial mapping/ablation during VT (entrainment mapping, activation mapping) and/or substrate mapping in sinus rhythm (elimination of fractionated/late potentials, endocardial scar homogenization) with remote magnetic navigation (Niobe, Stereotaxis Inc.,St Louis, USA) and irrigated RF ablation (NaviStar RMT ThermoCool, Biosense Webster,California, USA).
Intervention Type
Device
Intervention Name(s)
Magnetic irrigated ablation catheter
Other Intervention Name(s)
Niobe, Stereotaxis, Navigant
Intervention Description
Magnetic irrigated catheter to be used with the magnetic navigation system
Primary Outcome Measure Information:
Title
Percentage of Participants Free From VT at 1 Year Post-Treatment
Description
In order to qualify for inclusion in the chronic success statistic, patients must first be an acute success and must have had no VTs identified in their ICD history post ablation therapy.
Time Frame
1 Year follow-up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subject must be between the ages of 18 - 80 years Willing to provide prior written informed consent per local ethics committee guidelines Subjects must present with ventricular tachycardia, characterized by: history of myocardial scar and spontaneous ventricular tachycardia Able to be safely exposed to static magnetic fields No in-situ devices are present or any in-situ devices have been verified to be compatible to magnetic fields Exclusion Criteria: Presence of a mobile ventricular thrombus Inability to access the left ventricle Subjects must not have any contraindications to short-term anticoagulation Subjects must not have a life expectancy of <1 year due to a medical illness
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Petr Neuzil, MD
Organizational Affiliation
Na Homolce Hospital, Prague, CZ
Official's Role
Principal Investigator
Facility Information:
Facility Name
Krannert Institute of Cardiology
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46202
Country
United States
Facility Name
Hospital of the University of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Facility Name
Na Homolce Hospital
City
Prague
ZIP/Postal Code
15630
Country
Czech Republic
Facility Name
Herzzentrum Universitat Leipzig
City
Leipzig
ZIP/Postal Code
04289
Country
Germany

12. IPD Sharing Statement

Links:
URL
http://www.stereotaxis.com
Description
Study Sponsor

Learn more about this trial

Stereotaxis Study To Obliterate Persistent Ventricular Tachycardia

We'll reach out to this number within 24 hrs